It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IPSEY’s FA Score shows that 2 FA rating(s) are green whileLVRLF’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IPSEY’s TA Score shows that 5 TA indicator(s) are bullish while LVRLF’s TA Score has 3 bullish TA indicator(s).
IPSEY (@Pharmaceuticals: Other) experienced а -0.59% price change this week, while LVRLF (@Pharmaceuticals: Other) price change was +14.33% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.61%. For the same industry, the average monthly price growth was +3.66%, and the average quarterly price growth was +73.67%.
IPSEY is expected to report earnings on Oct 22, 2025.
LVRLF is expected to report earnings on May 30, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
IPSEY | LVRLF | IPSEY / LVRLF | |
Capitalization | 10.4B | 18.6M | 55,914% |
EBITDA | 889M | -2.57M | -34,585% |
Gain YTD | 6.825 | 0.163 | 4,200% |
P/E Ratio | 23.47 | N/A | - |
Revenue | 3.28B | 4.45M | 73,836% |
Total Cash | 438M | 746K | 58,713% |
Total Debt | 1.2M | 5.81M | 21% |
IPSEY | LVRLF | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 18 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | 50 Fair valued | |
PROFIT vs RISK RATING 1..100 | 41 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 53 | 95 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IPSEY's Valuation (50) in the null industry is in the same range as LVRLF (50). This means that IPSEY’s stock grew similarly to LVRLF’s over the last 12 months.
IPSEY's Profit vs Risk Rating (41) in the null industry is somewhat better than the same rating for LVRLF (100). This means that IPSEY’s stock grew somewhat faster than LVRLF’s over the last 12 months.
IPSEY's SMR Rating (100) in the null industry is in the same range as LVRLF (100). This means that IPSEY’s stock grew similarly to LVRLF’s over the last 12 months.
IPSEY's Price Growth Rating (53) in the null industry is somewhat better than the same rating for LVRLF (95). This means that IPSEY’s stock grew somewhat faster than LVRLF’s over the last 12 months.
IPSEY's P/E Growth Rating (100) in the null industry is in the same range as LVRLF (100). This means that IPSEY’s stock grew similarly to LVRLF’s over the last 12 months.
IPSEY | LVRLF | |
---|---|---|
RSI ODDS (%) | 2 days ago65% | N/A |
Stochastic ODDS (%) | 2 days ago65% | 2 days ago80% |
Momentum ODDS (%) | 2 days ago60% | 2 days ago90% |
MACD ODDS (%) | 2 days ago56% | 2 days ago68% |
TrendWeek ODDS (%) | 2 days ago52% | 2 days ago90% |
TrendMonth ODDS (%) | 2 days ago54% | 2 days ago90% |
Advances ODDS (%) | 9 days ago53% | N/A |
Declines ODDS (%) | N/A | 3 days ago90% |
BollingerBands ODDS (%) | 2 days ago56% | 2 days ago81% |
Aroon ODDS (%) | 2 days ago57% | 2 days ago90% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
NSEP | 27.50 | 0.03 | +0.10% |
Innovator Growth-100 Pwr Buffr ETF - Sep | |||
KNG | 49.38 | -0.54 | -1.08% |
FT Cboe Vest S&P 500® Dv Ast Tgt Inc ETF | |||
VNM | 15.04 | -0.20 | -1.31% |
VanEck Vietnam ETF | |||
INDS | 36.54 | -0.49 | -1.32% |
Pacer Benchmark Industrial RE SCTR ETF | |||
FTDS | 52.55 | -0.98 | -1.83% |
First Trust Dividend Strength ETF |
A.I.dvisor tells us that IPSEY and LBTSF have been poorly correlated (+15% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IPSEY and LBTSF's prices will move in lockstep.
Ticker / NAME | Correlation To IPSEY | 1D Price Change % | ||
---|---|---|---|---|
IPSEY | 100% | -0.59% | ||
LBTSF - IPSEY | 15% Poorly correlated | N/A | ||
LVRLF - IPSEY | 9% Poorly correlated | +24.81% | ||
HYPMY - IPSEY | 7% Poorly correlated | +4.71% | ||
IPSEF - IPSEY | 6% Poorly correlated | N/A | ||
INDV - IPSEY | 5% Poorly correlated | -1.54% | ||
More |
A.I.dvisor tells us that LVRLF and GNMLF have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LVRLF and GNMLF's prices will move in lockstep.
Ticker / NAME | Correlation To LVRLF | 1D Price Change % | ||
---|---|---|---|---|
LVRLF | 100% | +24.81% | ||
GNMLF - LVRLF | 20% Poorly correlated | N/A | ||
MCUJF - LVRLF | 14% Poorly correlated | N/A | ||
IPSEY - LVRLF | 9% Poorly correlated | -0.59% | ||
MEDIF - LVRLF | 8% Poorly correlated | +0.33% | ||
KSPHF - LVRLF | 5% Poorly correlated | N/A | ||
More |